Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Intensity Therapeutics, Inc. (INTS)
USD4.84
-0.03 (-0.62%)
US NASDAQ Healthcare Biotechnology
Address
61 Wilton Road 6880
Westport, CT, US
Westport, CT, US
CEO
Lewis H. Bender
Website
intensitytherapeutics.com
IPO
2023-06-30
CIK 1567264 ISIN US45828J2024
Description
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.84
-0.03 (-0.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
38.9K
Beta
3.06
Float Shares
1.02M
Free Float %
53.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.40% | -5.61% | -10.62% | -21.92% | -59.16% | -52.44% | -62.29% | -96.72% | -96.72% | -96.72% | -96.72% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
4.84
Low
125.00
+2,482.6%
Consensus
125.00
+2,482.6%
Median
125.00
+2,482.6%
High
125.00
+2,482.6%
DCF (Unlevered)
0.83
-82.8%
DCF (Levered)
0.87
-82.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
125.00
+2,482.6%
|
Quality scores
Altman Z-Score
-8.88
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+70.7% ★ Q1'26: +82.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-18,418.5% Q1'26: +6,161.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2,338.3% Q1'26: +4,075.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
3.00M
3.00M – 3.00M
|
351.0K
351.0K – 351.0K
-88.3% YoY
|
52.45M
52.45M – 52.45M
+14,842.0% YoY
|
211.88M
211.88M – 211.88M
+304.0% YoY
|
321.00M
321.00M – 321.00M
+51.5% YoY
|
| EBITDA |
-16.27M
|
-11.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-16.27M
|
-11.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-16.27M
est: -16.20M (-0.4%)
|
-11.61M
est: -106.79M (+89.1%)
|
-53.90M
-53.90M – -53.90M
+49.5% YoY
|
-49.33M
-49.33M – -49.33M
+8.5% YoY
|
-70.32M
-98.79M – -41.86M
-42.6% YoY
|
99.29M
99.29M – 99.29M
+241.2% YoY
|
175.51M
175.51M – 175.51M
+76.8% YoY
|
| SGA |
6.09M
|
5.19M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-29.25
est: -29.25 (+0.0%)
|
-8.56
est: -7.87 (-8.7%)
|
-3.97
-3.97 – -3.97
+49.5% YoY
|
-3.64
-3.64 – -3.64
+8.5% YoY
|
-5.37
-7.28 – -3.09
-47.7% YoY
|
7.32
7.32 – 7.32
+236.3% YoY
|
12.94
12.94 – 12.94
+76.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
35
Total invested
1.58M
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Management, LLC | 745.9K | 5.40% | 745.9K | — | 745.9K | — | CO | Delaware | 2024-06-07 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
35
+9 vs prev Q
New positions
10
Closed positions
1
Increased
24
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 649.1K +393.2K (+153.6%) | 266.1K +203.9K (+327.9%) | 3.44% +2.084 pp | 0.00% +0.000 pp | USD0.70 -41.4% | 9 qtrs — |
| 2 | SAPIENT CAPITAL LLC | 650.2K -326.6K (-33.4%) | 244.2K +4.5K (+1.9%) | 3.45% -1.731 pp | 0.00% 0.000 pp | USD5.57 -92.6% | 9 qtrs — |
| 3 | SENTINUS, LLC | 495.9K +14.7K (+3.1%) | 203.4K +86.6K (+74.2%) | 2.63% +0.078 pp | 0.02% -0.006 pp | USD0.37 +10.8% | 8 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 460.2K +201.4K (+77.8%) | 188.8K +126.0K (+200.5%) | 2.44% +1.067 pp | 0.00% +0.000 pp | USD1.06 -61.3% | 10 qtrs — |
| 5 | MESIROW FINANCIAL INVESTMENT MANAGEMENT, INC. | 251.0K +51.0K (+25.5%) | 103.0K +54.4K (+112.1%) | 1.33% +0.270 pp | 0.00% +0.001 pp | USD1.03 -60.2% | 9 qtrs — |
| 6 | LEGACY ADVISORS, LLC | 153.4K +153.4K (+100.0%) | 62.9K +62.9K (+100.0%) | 0.81% +0.813 pp | 0.01% +0.007 pp | USD0.41 +0.0% | 1 qtrs NEW |
| 7 | CREATIVE PLANNING | 143.1K +143.1K (+100.0%) | 58.7K +58.7K (+100.0%) | 0.76% +0.759 pp | 0.00% +0.000 pp | USD0.41 +0.0% | 1 qtrs NEW |
| 8 | STATE STREET CORP | 136.2K +121.7K (+839.3%) | 55.9K +52.4K (+1,487.6%) | 0.72% +0.645 pp | 0.00% +0.000 pp | USD1.28 -68.0% | 9 qtrs — |
| 9 | BROWN ADVISORY INC | 130.0K -72.0 (-0.1%) | 53.3K +21.8K (+68.9%) | 0.69% 0.000 pp | 0.00% +0.000 pp | USD4.99 -91.8% | 8 qtrs — |
| 10 | CI PRIVATE WEALTH, LLC | 100.0K +100.0K (+100.0%) | 41.0K +41.0K (+100.0%) | 0.53% +0.530 pp | 0.00% +0.000 pp | USD0.41 +0.0% | 1 qtrs NEW |
| 11 | STONEBRIDGE FINANCIAL GROUP, LLC | 77.4K +23.0K (+42.3%) | 31.7K +18.5K (+140.5%) | 0.41% +0.122 pp | 0.00% +0.002 pp | USD0.49 -16.3% | 5 qtrs — |
| 12 | NORTHERN TRUST CORP | 75.5K +61.5K (+438.7%) | 31.0K +27.6K (+810.3%) | 0.40% +0.326 pp | 0.00% +0.000 pp | USD0.70 -41.4% | 4 qtrs — |
| 13 | WARBERG ASSET MANAGEMENT LLC | 69.0K +9.0K (+15.0%) | 28.1K +13.5K (+93.0%) | 0.37% +0.048 pp | 0.00% +0.001 pp | USD0.32 +28.1% | 3 qtrs — |
| 14 | JANE STREET GROUP, LLC | 62.8K +62.8K (+100.0%) | 25.7K +25.7K (+100.0%) | 0.33% +0.333 pp | 0.00% +0.000 pp | USD0.41 +0.0% | 3 qtrs — |
| 15 | SIGMA PLANNING CORP | 56.4K -12.7K (-18.4%) | 23.1K +6.4K (+37.9%) | 0.30% -0.068 pp | 0.00% +0.000 pp | USD3.18 -87.1% | 10 qtrs — |
| 16 | IHT WEALTH MANAGEMENT, LLC | 50.5K +3.0K (+6.3%) | 20.7K +9.2K (+79.7%) | 0.27% +0.016 pp | 0.00% +0.000 pp | USD0.25 +64.0% | 2 qtrs — |
| 17 | VIRTU FINANCIAL LLC | 48.7K +22.7K (+87.6%) | 20.0K +14.0K (+233.3%) | 0.26% +0.121 pp | 0.00% +0.000 pp | USD0.34 +20.6% | 3 qtrs — |
| 18 | EWA, LLC | 41.4K +22.1K (+115.2%) | 17.0K +12.3K (+263.7%) | 0.22% +0.117 pp | 0.00% +0.003 pp | USD0.36 +13.9% | 3 qtrs — |
| 19 | TWO SIGMA SECURITIES, LLC | 34.8K +16.4K (+88.8%) | 14.3K +9.8K (+219.1%) | 0.18% +0.087 pp | 0.00% +0.001 pp | USD0.32 +28.1% | 2 qtrs — |
| 20 | ONE CHARLES PRIVATE WEALTH SERVICES, LLC | 31.8K +— (+0.0%) | 13.0K +5.3K (+69.0%) | 0.17% +0.000 pp | 0.00% +0.001 pp | USD4.99 -91.8% | 8 qtrs — |
| 21 | BLAIR WILLIAM & CO/IL | 30.2K -7.6K (-20.1%) | 12.4K +3.2K (+35.0%) | 0.16% -0.040 pp | 0.00% +0.000 pp | USD4.92 -91.7% | 7 qtrs — |
| 22 | UBS GROUP AG | 25.4K -110.8K (-81.4%) | 10.4K -22.7K (-68.5%) | 0.13% -0.587 pp | 0.00% +0.000 pp | USD0.33 +24.2% | 9 qtrs — |
| 23 | NEWEDGE ADVISORS, LLC | 25.0K +25.0K (+100.0%) | 10.3K +10.3K (+100.0%) | 0.13% +0.133 pp | 0.00% +0.000 pp | USD0.41 +0.0% | 1 qtrs NEW |
| 24 | TOWER RESEARCH CAPITAL LLC (TRC) | 21.5K +4.8K (+29.0%) | 8.8K +4.8K (+118.1%) | 0.11% +0.026 pp | 0.00% +0.000 pp | USD0.64 -35.9% | 10 qtrs — |
| 25 | QTR FAMILY WEALTH, LLC | 17.4K +— (+0.0%) | 6.5K +2.3K (+54.3%) | 0.09% +0.000 pp | 0.00% +0.001 pp | USD1.97 -79.2% | 4 qtrs — |
| 26 | SASSICAIA CAPITAL ADVISERS LLC | 15.0K -5.0K (-25.0%) | 6.2K +1.3K (+26.8%) | 0.08% -0.027 pp | 0.01% +0.011 pp | USD0.24 +70.8% | 2 qtrs — |
| 27 | MAREX GROUP PLC | 15.0K +15.0K (+100.0%) | 6.2K +6.2K (+100.0%) | 0.08% +0.080 pp | 0.00% +0.000 pp | USD0.41 +0.0% | 1 qtrs NEW |
| 28 | — | 13.6K +13.6K (+100.0%) | 5.6K +5.6K (+100.0%) | 0.07% +0.072 pp | 0.01% +0.007 pp | USD0.41 +0.0% | 1 qtrs NEW |
| 29 | VONTOBEL HOLDING LTD. | 12.0K +12.0K (+100.0%) | 4.9K +4.9K (+100.0%) | 0.06% +0.064 pp | 0.00% +0.000 pp | USD0.41 +0.0% | 1 qtrs NEW |
| 30 | BEACON POINTE ADVISORS, LLC | 10.2K +10.2K (+100.0%) | 4.2K +4.2K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.000 pp | USD0.41 +0.0% | 1 qtrs NEW |
| 31 | PENSIONMARK FINANCIAL GROUP, LLC | 10.0K +10.0K (+100.0%) | 4.1K +4.1K (+100.0%) | 0.05% +0.053 pp | 0.00% +0.000 pp | USD0.41 +0.0% | 1 qtrs NEW |
| 32 | CIBC PRIVATE WEALTH GROUP, LLC | 5.0K +25.0 (+0.5%) | 2.1K +847.0 (+69.8%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD0.31 +32.3% | 3 qtrs — |
| 33 | BANK OF AMERICA CORP /DE/ | 584.00 -36.0 (-5.8%) | 240.00 +90.0 (+60.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.68 -39.7% | 9 qtrs — |
| 34 | MORGAN STANLEY | 500.00 +— (+0.0%) | 205.00 +84.0 (+69.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.92 -91.7% | 7 qtrs — |
| 35 | CITIGROUP INC | 88.00 -44.5K (-99.8%) | 36.00 -10.8K (-99.7%) | 0.00% -0.236 pp | 0.00% +0.000 pp | USD0.24 +70.8% | 2 qtrs — |
| 36 | SCIENTECH RESEARCH LLC | — -24.7K (-100.0%) | — -6.0K (-100.0%) | 0.00% -0.131 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 114.0K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
9
Sells
0
Shares acquired
1.38M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,383,924
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-26 | BENDER LEWIS H | Director / Officer | A-Award | A | Common Stock, $0.0001 Par Value | 37,749 | 6.11 | 230.6K | 118,549 | D | ↗ |
| 2025-12-31 | Wesolowski John M | Officer | A-Award | A | Common Stock, $0.0001 Par Value | 8,918 | 0.26 | 2.3K | 85,354 | D | ↗ |
| 2025-12-31 | Talamo Joseph | Officer | A-Award | A | Common Stock, $0.0001 Par Value | 14,482 | 0.26 | 3.8K | 28,661 | D | ↗ |
| 2025-06-30 | Wesolowski John M | Officer | A-Award | A | Common Stock, $0.0001 Par Value | 69,745 | 0.26 | 18.2K | 76,436 | D | ↗ |
| 2025-06-30 | Talamo Joseph | Officer | A-Award | A | Common Stock, $0.0001 Par Value | 14,179 | 0.26 | 3.7K | 14,179 | D | ↗ |
| 2025-05-02 | Wesolowski John M | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 100,000 | 0.57 | 57.0K | 100,000 | D | ↗ |
| 2025-05-02 | Talamo Joseph | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 300,000 | 0.57 | 171.0K | 300,000 | D | ↗ |
| 2025-05-02 | Leahy Emer | Director | A-Award | A | Stock Option (right to buy Common Stock) | 50,000 | 0.57 | 28.5K | 50,000 | D | ↗ |
| 2025-05-02 | GOLDBERG MARK A | Director | A-Award | A | Stock Option (right to buy Common Stock) | 50,000 | 0.57 | 28.5K | 50,000 | D | ↗ |
| 2025-05-02 | Donovan Daniel | Director | A-Award | A | Stock Option (right to buy Common Stock) | 50,000 | 0.57 | 28.5K | 50,000 | D | ↗ |
| 2025-05-02 | DUBIN THOMAS I H | Director | A-Award | A | Stock Option (right to buy Common Stock) | 50,000 | 0.57 | 28.5K | 50,000 | D | ↗ |
| 2025-05-02 | BENDER LEWIS H | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy Common Stock) | 700,000 | 0.57 | 399.0K | 700,000 | D | ↗ |
| 2024-10-21 | Wesolowski John M | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 70,028 | 3.44 | 240.9K | 70,028 | D | ↗ |
| 2024-10-21 | Talamo Joseph | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 427,379 | 3.44 | 1.47M | 427,379 | D | ↗ |
| 2024-06-05 | Wesolowski John M | Officer | M-Exempt | D | Stock Option (right to buy Common Stock) | 1,000 | 4.00 | 4.0K | 14,000 | — | ↗ |
| 2024-05-14 | DUBIN THOMAS I H | Director | A-Award | A | Stock Option (right to buy Common Stock) | 50,000 | 4.42 | 221.0K | 50,000 | — | ↗ |
| 2024-03-06 | Wesolowski John M | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 25,000 | 5.19 | 129.8K | 25,000 | — | ↗ |
| 2024-03-06 | Leahy Emer | Director | A-Award | A | Stock Option (right to buy Common Stock) | 50,000 | 5.19 | 259.5K | 50,000 | — | ↗ |
| 2024-03-06 | GOLDBERG MARK A | Director | A-Award | A | Stock Option (right to buy Common Stock) | 50,000 | 5.19 | 259.5K | 50,000 | — | ↗ |
| 2024-03-06 | Donovan Daniel | Director | A-Award | A | Stock Option (right to buy Common Stock) | 50,000 | 5.19 | 259.5K | 50,000 | — | ↗ |
| 2024-03-06 | BENDER LEWIS H | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy Common Stock) | 464,805 | 5.19 | 2.41M | 464,805 | — | ↗ |
| 2023-12-11 | Talamo Joseph | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 80,000 | 6.88 | 550.4K | 80,000 | — | ↗ |
| 2023-07-19 | Wesolowski John M | Officer | A-Award | A | Stock Option (right to buy Common Stock) | 50,000 | 6.43 | 321.5K | 50,000 | — | ↗ |
| 2023-06-29 | Wesolowski John M | Officer | — | D | Stock Option (right to buy Common Stock) | 7,500 | 8.00 | 60.0K | 0 | — | ↗ |
| 2023-06-29 | Leahy Emer | Director | — | D | Stock Option (right to buy Common Stock) | 10,000 | 4.00 | 40.0K | 0 | — | ↗ |
| 2023-06-29 | GOLDBERG MARK A | Director | — | D | Stock Option (right to buy Common Stock) | 25,000 | 11.50 | 287.5K | 0 | — | ↗ |
| 2023-06-29 | Donovan Daniel | Director | — | D | Stock Option (right to buy Common Stock) | 25,000 | 9.00 | 225.0K | 0 | — | ↗ |
| 2023-06-29 | BENDER LEWIS H | Director / Officer / 10% Owner | — | D | Stock Option (right to buy Common Stock) | 75,000 | 9.00 | 675.0K | 0 | — | ↗ |
| 2023-06-29 | Ahlers James M | Officer | — | D | Warrants (Right to buy Common Stock) | 5,000 | 9.00 | 45.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.89M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Lewis H. Bender President and Chief Executive Officer | 549.2K | 411.9K | — | 340.1K | — | 54.3K | 1.36M | 25.09% | ↗ |
| 2 | 2025 | Joseph Talamo Chief Financial Officer | 374.7K | 152.4K | — | 147.7K | — | 48.9K | 723.7K | 20.41% | ↗ |
| 3 | 2025 | John Wesolowski Principal Accounting Officer and Controller | 246.8K | 75.0K | — | 49.2K | — | 7.4K | 378.5K | 13.01% | ↗ |
| 4 | 2024 | Lewis H. Bender President and Chief Executive Officer | 544.1K | — | — | 1.89M | — | 52.9K | 2.49M | 75.99% | ↗ |
| 5 | 2024 | Joseph Talamo Chief Financial Officer | 370.0K | — | — | 1.25M | — | 46.9K | 1.66M | 74.92% | ↗ |
| 6 | 2024 | John Wesolowski Principal Accounting Officer and Controller | 251.3K | — | — | 308.2K | — | 9.6K | 569.1K | 54.16% | ↗ |
| 7 | 2023 | Lewis H. Bender President and Chief Executive Officer | 553.2K | 392.3K | — | — | — | 290.3K | 1.24M | 0.00% | ↗ |
| 8 | 2023 | John Wesolowski Principal Accounting Officer and Controller | 186.2K | 67.0K | — | 254.9K | — | 19.2K | 527.3K | 48.35% | ↗ |
| 9 | 2023 | Joseph Talamo Chief Financial Officer | 14.2K | — | — | 442.1K | — | — | 456.4K | 96.88% | ↗ |
| 10 | 2022 | Lewis H. Bender President and Chief Executive Officer | 492.8K | — | — | 439.4K | — | 62.3K | 994.6K | 44.18% | ↗ |
| 11 | 2022 | John Wesolowski Principal Accounting Officer and Controller | 165.0K | — | — | 81.2K | — | 5.0K | 251.2K | 32.33% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lewis H. Bender | Founder, President, Chief Executive Officer & Chairman of the Board | 1M | male |
| Joseph Talamo | Chief Financial Officer | 576.0K | male |
| John Wesolowski | Principal Accounting Officer & Controller | 329.2K | male |
| James Ahlers | Executive Vice President of Corporate Finance | 75.1K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INTS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
